ABSTRACT
Practical management of DLB, reecting the widespread impact of the core pathology of alpha-synuclein across multiple neural systems (both peripheral and central), oen means that clinicians need to consider a wide range of concurrent treatments targeting dierent symptom clusters (Figure 63.1).
